Veru (VERU) executive Barnette received 27,000 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
K Gary Barnette (Chief Scientific Officer at Veru Inc., VERU) reported that they received 27,000 shares on Dec 5, 2025.
- Reporting person
- Barnette K Gary
- Role
- Chief Scientific Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | Grant or award (A) | Common Stock OptionOn 27,000 Common Stock1 | +27,000 | - | - | 27,000 direct |
Holdings before and after
- Common Stock Option: 0 to 27,000 direct
Footnotes from the filing
- 1. Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Barnette report in this VERU Form 4?
K Gary Barnette (Chief Scientific Officer at Veru Inc., VERU) reported that they received 27,000 shares on Dec 5, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for VERU
Across the 3 sessions after earlier VERU headlines, the stock closed higher 0 times and lower 2 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VERU | SPY |
|---|---|---|---|
| Dec 4, 2025 | Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop | +0.0% | +0.1% |
| Oct 31, 2025 | Veru to Present Two Abstracts at ObesityWeek 2025 | -2.0% | +0.3% |
| Oct 30, 2025 | Veru Announces Pricing of $25 Million Public Offeringand 1 other headline that session | -14.0% | -1.1% |
Earlier insider filings at VERU
- Dec 9, 2025SEC Form 4 filed by Director Rankowitz Michael L
- Dec 9, 2025SEC Form 4 filed by Director Katzovitz Loren Mark
- Dec 9, 2025SEC Form 4 filed by President and CEO Steiner Mitchell Shuster
- Dec 9, 2025SEC Form 4 filed by Director Hyun Grace
- Dec 9, 2025SEC Form 4 filed by Chief Admin Officer and CFO Greco Michele
Keep researching VERU
- VERU insider tradesEvery buy and sale reported by Veru Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- VERU earnings historyPast Veru Inc. earnings releases, newest first.
- VERU financial statementsRevenue, profit, cash flow and balance sheet from Veru Inc.'s SEC filings.
Quantisnow market dataNASDAQ
VERU
Veru Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for VERU
Full VERU profile on Quantisnow Follow VERU and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time